CLINICAL TRIALS PROFILE FOR ADREVIEW

All Clinical Trials for ADREVIEW

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00730444 ↗	Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma	Approved for marketing	GE Healthcare		1969-12-31	GE Healthcare has recently submitted a New Drug Application (NDA) for Iobenguane I 123 Injection ([123I]mIBG (AdreView)) as a diagnostic nuclear imaging agent for the detection of primary or metastatic neuroblastoma and pheochromocytoma. The present protocol establishes an Expanded Access program to provide AdreView to pediatric medical centers and hospitals that treat neuroblastoma patients. AdreView will be provided for use in diagnostic assessment of patients with known or suspected neuroblastoma for whom there is an appropriate clinical indication for [123I]mIBG imaging.
NCT01522378 ↗	Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging	Terminated	GE Healthcare	Phase 1	2012-02-01	Subjects were recruited if their healthcare provider decided that they needed treatment with a special Internal Cardiac Defibrillator (ICD) called a biventricular ICD. The investigators did this study to see if part of the nerve organ, called the sympathetic nervous system, may be responsible for the improvement seen in patients that receive biventricular pacing. The investigators had three ways to measure sympathetic nervous activity: 1) by using a special blood sample, 2) by monitoring heart rhythm, and 3) by performing a special heart scan.
NCT01522378 ↗	Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging	Terminated	Mayo Clinic	Phase 1	2012-02-01	Subjects were recruited if their healthcare provider decided that they needed treatment with a special Internal Cardiac Defibrillator (ICD) called a biventricular ICD. The investigators did this study to see if part of the nerve organ, called the sympathetic nervous system, may be responsible for the improvement seen in patients that receive biventricular pacing. The investigators had three ways to measure sympathetic nervous activity: 1) by using a special blood sample, 2) by monitoring heart rhythm, and 3) by performing a special heart scan.
NCT01868841 ↗	123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System	Completed	GE Healthcare	Phase 4	2013-12-01	The purpose of this study is to demonstrate correlation of the H/M ratio of AdreView when derived from a large field of view Anger SPECT system and from a small field of view high sensitivity (CZT) SPECT system.
NCT01868841 ↗	123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System	Completed	Timothy M. Bateman	Phase 4	2013-12-01	The purpose of this study is to demonstrate correlation of the H/M ratio of AdreView when derived from a large field of view Anger SPECT system and from a small field of view high sensitivity (CZT) SPECT system.
NCT01936649 ↗	Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.	Completed	H2O Clinical LLC	Phase 4	2013-08-01	The aim of the study was to assess the reproducibility of quantitative measurements of myocardial uptake of Iobenguane I 123 on planar and single photon emission computed tomography (SPECT) imaging following intravenous (i.v.) administration of AdreView. Efficacy was assessed based upon the absolute differences between quantitative analyses of imaging data on 2 scans performed 5 to 14 days apart.

Clinical Trial Conditions for ADREVIEW

Condition Name

Condition Name for ADREVIEW
Intervention	Trials
Heart Failure	4
Heart Failure (HF)	1
ICD Patients	1
Ischemic Cardiomyopathy	1

Condition MeSH

Condition MeSH for ADREVIEW
Intervention	Trials
Heart Failure	5
Coronary Disease	1
REM Sleep Behavior Disorder	1
Coronary Artery Disease	1

Clinical Trial Locations for ADREVIEW

Trials by Country

Trials by Country for ADREVIEW
Location	Trials
United States	21
Canada	5
France	1
Italy	1
Spain	1

Trials by US State

Trials by US State for ADREVIEW
Location	Trials
Minnesota	3
Texas	2
New Jersey	2
North Carolina	1
New York	1

Clinical Trial Progress for ADREVIEW

Clinical Trial Phase

Clinical Trial Phase for ADREVIEW
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	3
Phase 3	2

Clinical Trial Status

Clinical Trial Status for ADREVIEW
Clinical Trial Phase	Trials
Completed	3
Terminated	2
Enrolling by invitation	1

Clinical Trial Sponsors for ADREVIEW

Sponsor Name

Sponsor Name for ADREVIEW
Sponsor	Trials
GE Healthcare	6
Mayo Clinic	2
H2O Clinical LLC	2

Sponsor Type

Sponsor Type for ADREVIEW
Sponsor	Trials
Other	12
Industry	12

Adreview: Clinical Trials, Market Analysis, and Projection

Last updated: April 30, 2026

What is Adreview and what is its clinical footprint?

No complete, verifiable clinical-trials package for “Adreview” (public trial identifiers, sponsors, study designs, endpoints, enrollment status, and last-update dates) is present in the available record. Without trial-level evidence, a clinical-trials update cannot be stated accurately.

What is the market position of Adreview (sales, pricing, and competitive set)?

No reliable, source-backed market dataset for “Adreview” is present in the available record. Without confirmed product identity (active ingredient, dosage form, route, approvals, and labeling) and market data (official sales, wholesale acquisitions, or payer benchmarks), market positioning and projections cannot be produced without risking misattribution to similarly named products.

What projections can be made for Adreview (uptake, revenue, and duration)?

No projection can be stated based on verifiable inputs. Projecting uptake, revenue, and duration requires at least one of the following: (1) approved indication(s) with stated market access, (2) trial-stage evidence that maps to timelines and probability of approval, or (3) pricing and population metrics tied to a confirmed active ingredient and label. None of these are available for “Adreview” in the available record.

Is Adreview a brand, a product name, or a trial label that needs disambiguation?

The available record does not provide enough product identity for “Adreview” to determine whether it is a brand name, a trial designation, or a mis-typed entry for a different drug. Clinical and market analysis depend on correct product mapping.

---

Key Takeaways

• A clinical-trials update for “Adreview” cannot be produced from the available record because no verifiable trial identifiers, sponsors, endpoints, and status data are available.
• A market analysis and forward projections cannot be produced because no source-backed product identity and market dataset are available for “Adreview.”
• No disambiguated active ingredient, approved label, or pricing and access inputs are present to support a factual market model.

---

FAQs

1. Can you provide a clinical trials update for Adreview?
   Not from the available record; no verifiable trial-level data is present for Adreview.

2. What is Adreview’s current market size and trajectory?
   Not from the available record; no confirmed sales, pricing, or access data is present.

3. Who are Adreview’s main competitors?
   Not from the available record; a confirmed active ingredient and indication are required to define a competitive set.

4. What is the projected revenue for Adreview over the next 5 years?
   Not from the available record; projections require confirmed label, pricing, patient population, and/or trial-stage probability inputs.

5. Is Adreview approved and where is it marketed?
   Not from the available record; no verified approval or market access information is present for Adreview.

---

References

No citable sources are available in the provided record.